Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
Mais filtros

País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Br J Neurosurg ; 37(4): 634-636, 2023 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31342790

RESUMO

We report the fourth case of Carbapenem-resistant Klebsiella pneumoniae (CRKP) meningitis and the only one associated with brain abscess formation. A 29-years-old male patient developed septic shock 13 days after a right nasopharyngeal AVM resection. CRKP was grown from CSF with a MIC for meropenem ≥16 mg/L. Intravenous tigecycline and amikacin, combined with intrathecal amikacin and oral sulfamethoxazole were given. CSF culture was sterile on the 23rd day post operation. A right temporal lobe brain abscess formed by day 38 and was drained. Antibiotics were changed to oral sulfamethoxazole and minocycline for four weeks. The patient was cured with no relapse to date. With few cases reported we can only carefully recommend the combinational use of intravenous antibiotics with high dose intrathecal/intraventricular aminoglycosides.


Assuntos
Abscesso Encefálico , Enterobacteriáceas Resistentes a Carbapenêmicos , Infecção Hospitalar , Infecções por Klebsiella , Meningite , Pneumonia , Masculino , Humanos , Adulto , Amicacina/uso terapêutico , Infecções por Klebsiella/tratamento farmacológico , Infecções por Klebsiella/complicações , Klebsiella pneumoniae , Infecção Hospitalar/tratamento farmacológico , Antibacterianos/uso terapêutico , Meropeném/uso terapêutico , Meningite/tratamento farmacológico , Sulfametoxazol/uso terapêutico , Abscesso Encefálico/diagnóstico por imagem , Abscesso Encefálico/tratamento farmacológico , Abscesso Encefálico/cirurgia , Testes de Sensibilidade Microbiana
2.
Nat Commun ; 13(1): 302, 2022 01 18.
Artigo em Inglês | MEDLINE | ID: mdl-35042848

RESUMO

A 30-year-old bombing victim with a fracture-related pandrug-resistant Klebsiella pneumoniae infection after long-term (>700 days) antibiotic therapy is treated with a pre-adapted bacteriophage along with meropenem and colistin, followed by ceftazidime/avibactam. This salvage therapy results in objective clinical, microbiological and radiological improvement of the patient's wounds and overall condition. In support, the bacteriophage and antibiotic combination is highly effective against the patient's K. pneumoniae strain in vitro, in 7-day mature biofilms and in suspensions.


Assuntos
Antibacterianos/uso terapêutico , Farmacorresistência Bacteriana Múltipla , Fraturas Ósseas/microbiologia , Infecções por Klebsiella/microbiologia , Infecções por Klebsiella/terapia , Klebsiella pneumoniae/fisiologia , Terapia por Fagos , Adulto , Compostos Azabicíclicos/farmacologia , Compostos Azabicíclicos/uso terapêutico , Bacteriófagos/genética , Bacteriófagos/ultraestrutura , Biofilmes/efeitos dos fármacos , Ceftazidima/farmacologia , Ceftazidima/uso terapêutico , Ilhas de CpG/genética , Combinação de Medicamentos , Resistência Microbiana a Medicamentos/efeitos dos fármacos , Resistência Microbiana a Medicamentos/genética , Fraturas Ósseas/complicações , Fraturas Ósseas/diagnóstico por imagem , Genoma Viral , Humanos , Infecções por Klebsiella/complicações , Infecções por Klebsiella/diagnóstico por imagem , Klebsiella pneumoniae/efeitos dos fármacos , Klebsiella pneumoniae/genética , Klebsiella pneumoniae/isolamento & purificação , Testes de Sensibilidade Microbiana , Polimorfismo de Nucleotídeo Único/genética , Proteômica , Replicon/genética
3.
Bull Exp Biol Med ; 171(4): 458-460, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34542762

RESUMO

High efficiency of a combined preparation including synergistic polymyxin B and 4-hexylresorcinol was shown for treatment of experimental sepsis caused by an antibiotic-resistant highly virulent hypermucoid Klebsiella pneumoniae strain KPM9Pmr in mice. Complex therapy with polymyxin B (1 mg/kg) and 4-hexylresorcinol (30 mg/kg) led to cure in 80%; in 20% of these mice, no bacterial cells were found. After treatment with polymyxin B alone, only 50% animals survived and all of them contained bacterial cells. Comparative analysis of the results of monotherapy and combined treatment indicates that 4-hexylresorcinol not only increases the efficiency of antibiotic, but also minimizes persistence of the infection agent and therefore, the risk of development of antibiotic resistance.


Assuntos
Antibacterianos/uso terapêutico , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Hexilresorcinol/farmacologia , Klebsiella pneumoniae/efeitos dos fármacos , Sepse/tratamento farmacológico , Animais , Animais não Endogâmicos , Antibacterianos/farmacologia , Modelos Animais de Doenças , Sinergismo Farmacológico , Feminino , Infecções por Klebsiella/complicações , Infecções por Klebsiella/tratamento farmacológico , Infecções por Klebsiella/patologia , Klebsiella pneumoniae/patogenicidade , Camundongos , Testes de Sensibilidade Microbiana , Polimixina B/farmacologia , Polimixina B/uso terapêutico , Polimixinas/análogos & derivados , Polimixinas/farmacologia , Polimixinas/uso terapêutico , Sepse/microbiologia
4.
J Chemother ; 32(1): 15-20, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31713469

RESUMO

In this study, we aimed to investigate retrospectively the patients with carbapenem-resistant Enterobacteriaceae urinary tract infections (UTIs) in the terms of demographic findings, antibiotic sensitivity patterns and clinical features along with the treatment options. This study was performed at a tertiary-care educational university hospital. Adult (>18 years old) patients diagnosed with culture proven UTI due to carbapenem-resistant Klebsiella pneumoniae (between December 2016 to December 2017) were included in the study. Antimicrobial susceptibility testing of the isolates was performed with the VITEK 2 system (bioMérieux). Resistance to imipenem, ertapenem, and meropenem was tested by E-test (bioMérieux). The results were interpreted according to the EUCAST criteria. A total number of 100 patients (34% female, mean age 61.69 ± 1.65 years) were included in this study. One month all-cause mortality rate was 19%. Microbiologic eradication rate was 88.7% while it was significantly higher in combination therapy (65/70 vs. 14/19, p = 0.019) and carbapenem long-lasting (4 h) infusion subgroups (54/56 vs. 2/56, p = 0.005). Relapse and reinfection rates were 61.7 and 29.7%, respectively. Logistic regression analysis for mortality risk factors resulted as history of ertapenem usage (OR: 4.74, 95% CI: 0.678-33.201, p = 0.117), lack of microbiologic eradication (OR: 21.7, 95% CI: 1.906-247.375, p = 0.013) and ICU stay (OR: 54.8, 95% CI: 4.145-726.324, p = 0.002). Combination, carbapenem long-lasting infusion and double carbapenem therapies seem to result in higher microbiologic eradication rates and thus may effect the mortality rates of these group of patients. Randomized-controlled studies should be performed in this critical patient group to confirm these results.


Assuntos
Anti-Infecciosos/uso terapêutico , Enterobacteriáceas Resistentes a Carbapenêmicos , Infecções por Klebsiella/complicações , Infecções Urinárias/microbiologia , Proteínas de Bactérias , Resistência Microbiana a Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Klebsiella pneumoniae , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Estudos Retrospectivos , Infecções Urinárias/tratamento farmacológico , beta-Lactamases
5.
Clin Neurol Neurosurg ; 188: 105592, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-31760254

RESUMO

A 38-year-old male presented to the hospital with headache, fever, and meningeal signs. He had undergone a surgical review of a ventriculoperitoneal shunt system one month earlier. A head computed tomography scan showed hydrocephalus. His medical history included a human immunodeficiency virus infection identified four years before and resolved cryptococcal meningitis, which had necessitated the implantation of the shunt system. Ventricular cerebrospinal fluid (CSF) was obtained, which showed inflammation and, in culture, grew a Gram-negative bacillus identified as multidrug-resistant Klebsiella oxytoca. The shunt was removed and a ventricular drain was installed. Treatment with meropenem and amikacin was established without a response; the CSF white blood cell count continued to increase, with cultures remaining positive. The patient's clinical condition deteriorated to stupor. With informed consent, intraventricular (ITV) treatment with tigecycline was initiated at a dose of 5 mg every 24 h and, three days later, the CSF cultures were negativized. Tigecycline levels in the CSF were quantified by liquid chromatography with ultraviolet detection and showed peak concentrations achieved at two hours after the dose of between 178 and 310 µg/mL. After 11 days of treatment with ITV tigecycline and eight negative CSF cultures, a new CSF shunt was installed. During follow-up review 10 months later, the patient reported he was working. The dose of tigecycline used in this study produced levels 15 to 20 times the minimum inhibitory concentration of the bacteria for up to six hours with adequate tolerance.


Assuntos
Antibacterianos/uso terapêutico , Ventriculite Cerebral/tratamento farmacológico , Farmacorresistência Bacteriana Múltipla , Infecções por Klebsiella/tratamento farmacológico , Infecção da Ferida Cirúrgica/tratamento farmacológico , Tigeciclina/uso terapêutico , Derivação Ventriculoperitoneal , Adulto , Antibacterianos/líquido cefalorraquidiano , Fármacos Anti-HIV/uso terapêutico , Ventriculite Cerebral/complicações , Ventriculite Cerebral/diagnóstico , Ventriculite Cerebral/microbiologia , Combinação Efavirenz, Emtricitabina, Fumarato de Tenofovir Desoproxila/uso terapêutico , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Humanos , Injeções Intraventriculares , Infecções por Klebsiella/complicações , Infecções por Klebsiella/diagnóstico , Infecções por Klebsiella/microbiologia , Klebsiella oxytoca/isolamento & purificação , Klebsiella oxytoca/fisiologia , Masculino , Testes de Sensibilidade Microbiana , Infecção da Ferida Cirúrgica/complicações , Infecção da Ferida Cirúrgica/diagnóstico , Infecção da Ferida Cirúrgica/microbiologia , Tigeciclina/líquido cefalorraquidiano
6.
Pol Merkur Lekarski ; 46(276): 251-256, 2019 Jun 28.
Artigo em Polonês | MEDLINE | ID: mdl-31260434

RESUMO

Klebsiella pneumoniae belongs to the Enterobacteriaceae family and is responsible for 70% of human infections. From 20 to 80% strains of Klebsiella pneumoniae reveal resistance to first line antibiotics, including cephalosporins, fluoroquinolones and aminoglycosides, as well as carbapenems. Due to the resistance found in MDR (multidrug resistant) Klebsiella pneumoniae is classified according to the sequence types (ST), which are defined on the basis of the nucleotide sequence in the 7 loci (mdh, infB, tonB, gapA, phoE, pgi, and rpoB). Klebsiella pneumoniae uses several methods to protect against the effects of the human immune system. It affects receptors that recognize patterns expressed on epithelial cells and the immune system that are responsible for initiating signal cascades and phagocytic influences, including Toll-like receptors (TLRs) 2 and 4. Activates interleukins (IL) 12 (IL-12) and IL-23p40 by natural stimulation and leads to a decrease in the level of activation of interferon gamma (IFN-γ), IL-17, tumor necrosis factor (TNF-α) and IL-1ß, resulting in neutrophil and macrophage inflow and induction of humoral and cellular responses. Capsular polysaccharides and other components of the bacterial cell membrane protect it from the natural mechanisms of resistance, making it resistant to beta-defensins against bacteria. Increased virulence of Klebsiella pneumoniae is related to the protein structure associated with the capsule, especially in strains with increased virulence (HV - hypervirulent), lipopolysaccharides (LPS), siderophores and cilia (fimbriae). Today, two main types of Klebsiella pneumoniae strains are distinguished depending on the mechanism of resistance to antibiotics: strains that express beta-lactamases with extended spectrum (ESBL - extended spectrum beta-lactamases) that are resistant to cephalosporins and monobactams and strains that reveal the expression of carbapenemases, which they show resistance to available beta-lactams, including carbapenes. Polymyxins are useful in the treatment of patients infected with Klebsiella pneumoniae NDM (New Delhi metallo-beta-lactamase), where the effectiveness of therapy is greater when colistin is used together with carbapenem or rifampicin or tigecycline. The introduced abivactam in combination with ceftazidime is a promising therapeutic combination in severe infections. Similar clinical assessments were obtained with sulbactam, especially in combination with meropenem and colistin.


Assuntos
Infecções por Klebsiella , Klebsiella pneumoniae , Antibacterianos , Carbapenêmicos , Humanos , Infecções por Klebsiella/complicações , Infecções por Klebsiella/tratamento farmacológico , Klebsiella pneumoniae/isolamento & purificação , Testes de Sensibilidade Microbiana
7.
Int Urol Nephrol ; 50(1): 21-24, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29170899

RESUMO

PURPOSE: To determine the clinical utility of preoperative urine cultures in asymptomatic men undergoing prostate needle biopsy (PNB). METHODS: One hundred fifty asymptomatic men had urine cultures obtained 14-days prior to PNB. As per study protocol, positive cultures were not treated. Antibiotic prophylaxis prior to PNB included ciprofloxacin 500 mg the night before and morning of the biopsy. Repeat urine cultures were obtained immediately prior to PNB with colony-forming units (CFUs) annotated. Infectious complications post-biopsy were recorded. RESULTS: Of the 150 men, six patients (4%) had evidence of asymptomatic bacteriuria with > 10,000 CFU/mL on office urine culture. Repeat urine cultures on morning of biopsy in all 150 patients noted a mean bacterial count of 55 CFU/mL (range 0-1000). All six patients with positive office urine cultures had < 100 CFU/mL at time of PNB. Following biopsy, four patients (2.7%) developed an infectious complication including two with sepsis and two with culture-positive UTIs. The causative organism in all cases was quinolone-resistant E. coli. None of the six patients with preoperative positive urine cultures developed an infectious complication following PNB. CONCLUSIONS: In this prospective observational study, under 5% of asymptomatic men had positive office cultures prior to PNB. Furthermore, repeat urine culture on the morning of biopsy showed resolution in these patients, and none developed post-biopsy infectious complications. Routine office urine culture in the asymptomatic male prior to PNB was unnecessary.


Assuntos
Antibacterianos/uso terapêutico , Antibioticoprofilaxia , Bacteriúria/diagnóstico , Ciprofloxacina/uso terapêutico , Próstata/patologia , Sepse/etiologia , Infecções Urinárias/etiologia , Idoso , Doenças Assintomáticas , Bacteriúria/microbiologia , Biópsia por Agulha/efeitos adversos , Contagem de Colônia Microbiana , Infecções por Escherichia coli/complicações , Infecções por Escherichia coli/diagnóstico , Humanos , Infecções por Klebsiella/complicações , Infecções por Klebsiella/diagnóstico , Masculino , Pessoa de Meia-Idade , Período Pré-Operatório , Estudos Prospectivos , Sepse/microbiologia , Urinálise , Infecções Urinárias/microbiologia , Urina/microbiologia
8.
Mycopathologia ; 180(3-4): 237-43, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26045285

RESUMO

Majocchi's granuloma (MG) is a rare deep skin dermatophyte infection that can occur either in immunocompetent or in immunocompromised individuals. Oral itraconazole or terbinafine is considered to be the first choice of treatment. We report an immunocompetent man with deep nodular form of MG, the form which is generally found in immunosuppressed individuals. Previous treatment with either oral itraconazole or terbinafine yielded no apparent improvement. After a series of examination, the man was diagnosed as having Trichophyton rubrum-induced MG mixed with bacterial infection as evidenced by growth of Klebsiella pneumoniae in tissue bacterial culture. The patient was treated with a combination of cefoselis and levofloxacin for bacterial clearance followed by voriconazole treatment. After approximately 4 months of voriconazole treatment, the lesions completely resolved. Alternative medicine (voriconazole) can be considered in case of refractory infections during MG treatment.


Assuntos
Antifúngicos/administração & dosagem , Coinfecção/tratamento farmacológico , Granuloma/tratamento farmacológico , Tinha/tratamento farmacológico , Trichophyton/isolamento & purificação , Voriconazol/administração & dosagem , Antibacterianos/administração & dosagem , Ceftizoxima/administração & dosagem , Ceftizoxima/análogos & derivados , Coinfecção/complicações , Coinfecção/patologia , Granuloma/microbiologia , Granuloma/patologia , Humanos , Infecções por Klebsiella/complicações , Infecções por Klebsiella/tratamento farmacológico , Infecções por Klebsiella/patologia , Klebsiella pneumoniae/isolamento & purificação , Levofloxacino/administração & dosagem , Masculino , Pessoa de Meia-Idade , Tinha/complicações , Tinha/patologia , Resultado do Tratamento
9.
Fetal Pediatr Pathol ; 34(1): 18-20, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25166299

RESUMO

Glutathione synthetase deficiency (GSSD) is a rare disorder of glutathione metabolism with varying clinical severity. Patients may present with hemolytic anemia alone or together with acidosis and central nervous system impairment. Diagnosis is made by clinical presentation and detection of elevated concentrations of 5-oxoproline in urine and low glutathione synthetase activity in erythrocytes or cultured skin fibroblasts. The prognosis seems to depend on early diagnosis and treatment. We report a 4 months old Tunisian male infant who presented with severe metabolic acidosis with high anion gap and hemolytic anemia. High level of 5-oxoproline was detected in her urine and diagnosis of GSSD was made. Treatment consists of the correction of acidosis, blood transfusion, and supplementation with antioxidants. He died of severe metabolic acidosis and sepsis at the age of 15 months.


Assuntos
Erros Inatos do Metabolismo dos Aminoácidos/diagnóstico , Anemia Hemolítica/diagnóstico , Glutationa Sintase/deficiência , Glutationa Sintase/urina , Ácido Pirrolidonocarboxílico/urina , Acidose/complicações , Erros Inatos do Metabolismo dos Aminoácidos/complicações , Anemia Hemolítica/complicações , Antioxidantes/química , Eritrócitos/enzimologia , Evolução Fatal , Febre/complicações , Fibroblastos/enzimologia , Humanos , Lactente , Infecções por Klebsiella/complicações , Masculino , Sepse/complicações , Pele/citologia , Resultado do Tratamento , Tunísia
10.
Am J Emerg Med ; 33(2): 222-8, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25498529

RESUMO

OBJECTIVES: The objectives were to investigate the clinical characteristics of community-onset bacteremia in cirrhotic adults visiting the emergency department (ED), as well as the clinical impact of empirical antibiotics on their outcome. METHODS: Cirrhotic adults with community-onset bacteremia who visited the ED from January 2005 to December 2009 were included retrospectively. Clinical data and outcome were collected from the medical chart. The in vitro susceptibility was measured by the broth microdilution method. RESULTS: Of the 246 bacteremic episodes in cirrhotic patients, the major sources of bacteremia included intraabdominal infections (111, 45.1%), primary bacteremia (43, 17.5%), urinary tract infection (39, 15.9%), and soft tissue infection (22, 8.9%). Of the 258 bacteremic pathogens identified, Escherichia coli (83 isolates, 33.7%) and Klebsiella pneumoniae (61, 23.6%) were the most common microorganisms. In the multivariate analysis, delayed appropriate antibiotic therapy (>72 hours; odds ratio [OR], 4.29; P=.003), serum creatinine greater than 1.5 mg/dL at the ED (OR, 3.12; P=.005), severe sepsis (OR, 3.61; P=.01), Pittsburgh bacteremia score of at least 4 (OR, 2.66; P=.04), bacteremia due to pneumonia (OR, 5.44; P=.02), and a comorbidity of diabetes mellitus (OR, 3.54; P=.004) were independently associated with the 28-day mortality. CONCLUSIONS: Focusing on cirrhotic adults with community-onset bacteremia, we emphasized that the cirrhosis severity is one of the critical factors when choosing empirical antimicrobial therapy and that the strategy of empirical therapy is warranted for cirrhotic adults with severe decompensation (Child's C group). For critically ill patients, especially in those with Child's C group, only piperacillin/tazobactam, ertapenem, or imipenem treatment was warranted because of susceptibility rate of greater than 90%.


Assuntos
Bacteriemia/complicações , Cirrose Hepática/complicações , Antibacterianos/uso terapêutico , Bacteriemia/tratamento farmacológico , Bacteriemia/microbiologia , Infecções Comunitárias Adquiridas/complicações , Infecções Comunitárias Adquiridas/tratamento farmacológico , Infecções Comunitárias Adquiridas/microbiologia , Serviço Hospitalar de Emergência/estatística & dados numéricos , Infecções por Escherichia coli/complicações , Infecções por Escherichia coli/tratamento farmacológico , Feminino , Humanos , Infecções por Klebsiella/complicações , Infecções por Klebsiella/tratamento farmacológico , Klebsiella pneumoniae , Cirrose Hepática/tratamento farmacológico , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento
11.
Pan Afr Med J ; 18: 199, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25419326

RESUMO

The tropical diabetes hand syndrome is a complication affecting patients with diabetes mellitus in the tropics, and consists of localized cellulitis, swelling and ulceration of the hands which may progress to fulminant sepsis and gangrene of the whole limb. It is associated with a poor outcome. We report a 32 year old woman with tropical diabetes hand infection with autoamputation of the digits, review the relevant literature, and highlight the need for prevention and early hospital presentation in diabetics with hand infection, in order to prevent potentially crippling or fatal complications.


Assuntos
Celulite (Flegmão)/etiologia , Complicações do Diabetes/fisiopatologia , Deformidades Adquiridas da Mão/etiologia , Infecções por Klebsiella/complicações , Úlcera Cutânea/etiologia , Adulto , Glicemia/análise , Celulite (Flegmão)/microbiologia , Complicações do Diabetes/sangue , Diabetes Mellitus Tipo 2/complicações , Feminino , Humanos , Medicinas Tradicionais Africanas , Fator de Crescimento Derivado de Plaquetas/uso terapêutico , Fatores de Risco , Úlcera Cutânea/tratamento farmacológico , Infecção dos Ferimentos/etiologia
12.
Antimicrob Agents Chemother ; 57(11): 5394-7, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23959321

RESUMO

Polymyxins are reserved for salvage therapy of infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). Though synergy has been demonstrated for the combination of polymyxins with carbapenems or tigecycline, in vitro synergy tests are nonstandardized, and the clinical effect of synergy remains unclear. This study describes outcomes for patients with CRKP infections who were treated with polymyxin B monotherapy. We retrospectively reviewed the medical records of patients with CRKP infections who received polymyxin B monotherapy from 2007 to 2011. Clinical, microbiology, and antimicrobial treatment data were collected. Risk factors for treatment failure were identified by logistic regression. Forty patients were included in the analysis. Twenty-nine of 40 (73%) patients achieved clinical cure as defined by clinician-documented improvement in signs and symptoms of infections, and 17/32 (53%) patients with follow-up culture data achieved microbiological cure. End-of-treatment mortality was 10%, and 30-day mortality was 28%. In a multivariate analysis, baseline renal insufficiency was associated with a 6.0-fold increase in clinical failure after adjusting for septic shock (odds ratio [OR] = 6.0; 95% confidence interval [CI] = 1.22 to 29.59). Breakthrough infections with organisms intrinsically resistant to polymyxins occurred in 3 patients during the treatment. Eighteen of 40 (45%) patients developed a new CRKP infection a median of 23 days after initial polymyxin B treatment, and 3 of these 18 infections were polymyxin resistant. The clinical cure rate achieved in this retrospective study was 73% of patients with CRKP infections treated with polymyxin B monotherapy. Baseline renal insufficiency was a risk factor for treatment failure after adjusting for septic shock. Breakthrough infections with organisms intrinsically resistant to polymyxin B and development of resistance to polymyxin B in subsequent CRKP isolates are of concern.


Assuntos
Antibacterianos/uso terapêutico , Infecções por Klebsiella/tratamento farmacológico , Klebsiella pneumoniae/efeitos dos fármacos , Polimixina B/uso terapêutico , Insuficiência Renal Crônica/tratamento farmacológico , Resistência beta-Lactâmica , Adulto , Idoso , Idoso de 80 Anos ou mais , Carbapenêmicos/uso terapêutico , Farmacorresistência Bacteriana Múltipla , Feminino , Humanos , Infecções por Klebsiella/complicações , Infecções por Klebsiella/microbiologia , Infecções por Klebsiella/mortalidade , Klebsiella pneumoniae/crescimento & desenvolvimento , Modelos Logísticos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Insuficiência Renal Crônica/complicações , Insuficiência Renal Crônica/microbiologia , Insuficiência Renal Crônica/mortalidade , Estudos Retrospectivos , Fatores de Risco , Análise de Sobrevida , Falha de Tratamento
13.
Rev Iberoam Micol ; 30(4): 261-3, 2013.
Artigo em Espanhol | MEDLINE | ID: mdl-23318163

RESUMO

BACKGROUND: The significant increase in systemic fungal infections is mainly due to the increase in immunocompromised patients. The high morbimortality of these infections, along with the high hospitalization costs they generate, makes them a problem of great importance in our hospital practice. Saprochaete capitata is a rare fungus that causes invasive infections, usually in immunocompromised patients, and for which there is still no consensus on the treatment regimen to be used. CASE REPORT: We present a case of disseminated infection by this fungus in a heavily immunosuppressed patient, who died as a result of multiple organ failure despite the life support measures taken and the wide spectrum antibiotics. CONCLUSIONS: It is vital to begin the antibiotic treatment as soon as possible, as well as the monitoring and follow-up cultures to test for fungi in neutropenic patients.


Assuntos
Antifúngicos/uso terapêutico , Dipodascus/isolamento & purificação , Fungemia/microbiologia , Insuficiência de Múltiplos Órgãos/etiologia , Adulto , Anti-Infecciosos/uso terapêutico , Bacteriemia/microbiologia , Infecções por Citomegalovirus/complicações , Diagnóstico Diferencial , Dipodascus/efeitos dos fármacos , Quimioterapia Combinada , Esofagite/virologia , Evolução Fatal , Feminino , Fungemia/tratamento farmacológico , Fungemia/etiologia , Herpes Zoster/diagnóstico , Humanos , Hospedeiro Imunocomprometido , Infecções por Klebsiella/complicações , Lúpus Eritematoso Sistêmico/complicações , Testes de Sensibilidade Microbiana , Neutropenia/complicações
14.
Urologiia ; (4): 5-7, 2012.
Artigo em Russo | MEDLINE | ID: mdl-23116014

RESUMO

The efficacy of phytogenic drug prolit septo in the complex treatment of patients with urolithiasis complicated by infectious-inflammatory process was evaluated. The effects of prolit septo were assessed by a comparative evaluation of the results of microbiological analysis of urine in 14 patients of main group and 12 patients of control group. Patients in both groups were matched by sex, age, and results of raiological, clinical, biochemical and microbiological methods of examination. For the treatment of 11 patients of the main group, prolit septo was applied in combination with standard anti-bacterial treatment, 3 patients received monotherapy with prolit septo within 3-6 weeks. The drug was administered at a dose of 1200 mg (2 capsules) 3 times a day. Twelve patients of the control group received only standard treatment. The duration of treatment in both groups was 1-2 weeks. It was found that combined therapy with prolit septo is more effective than standard antibacterial treatment. Against the background of combined therapy the disappearance of bacteriuria was noted in 54.5% of patients of main group compared with 8.3% of patients of control group.


Assuntos
Bacteriúria/tratamento farmacológico , Enterococcus faecalis/efeitos dos fármacos , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Infecções por Klebsiella/tratamento farmacológico , Klebsiella pneumoniae/efeitos dos fármacos , Fitoterapia , Urolitíase/tratamento farmacológico , Adulto , Antibacterianos/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Bacteriúria/complicações , Bacteriúria/diagnóstico , Creatinina/sangue , Quimioterapia Combinada , Enterococcus faecalis/fisiologia , Feminino , Infecções por Bactérias Gram-Positivas/complicações , Infecções por Bactérias Gram-Positivas/diagnóstico , Humanos , Infecções por Klebsiella/complicações , Infecções por Klebsiella/diagnóstico , Klebsiella pneumoniae/fisiologia , Masculino , Pessoa de Meia-Idade , Phyllanthus , Extratos Vegetais/uso terapêutico , Urolitíase/complicações , Urolitíase/diagnóstico , Adulto Jovem
15.
Ophthalmology ; 119(11): 2358-63, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22817832

RESUMO

PURPOSE: Although endophthalmitis secondary to pyogenic liver abscess (PLA) is becoming a globally emerging infectious disease, population-based investigations evaluating the relationship between PLA and endogenous endophthalmitis remain scarce. This study aimed to investigate the incidence and risk of endogenous endophthalmitis in patients with PLA compared with unaffected individuals by using a nationwide, population-based dataset. DESIGN: Retrospective, cohort study. PARTICIPANTS AND CONTROLS: This study used data sourced from Taiwan's National Health Insurance Research Database. In total, 12 727 patients with PLA were included in the study group and 63 635 matched subjects were randomly extracted as a comparison group. METHODS: Stratified Cox proportional hazards regressions were performed to assess the effect of PLA on the hazard of developing endogenous endophthalmitis. MAIN OUTCOME MEASURES: The incidence and risk of endogenous endophthalmitis between the study group and comparison group. RESULTS: Of the total sample, 148 subjects (0.10%) were diagnosed with endophthalmitis during the 1-year follow-up period. Endophthalmitis was found in 106 patients (0.84%) with PLA and 42 comparison patients (0.07%). After adjusting for patient monthly income, geographic location, and urbanization level, those suffering from PLA were found to have a greater likelihood of developing endophthalmitis during the 1-year follow-up period than comparison patients (hazard ratio [HR], 12.83; 95% confidence interval, 8.94-18.41). Stratification did not reveal any large differences in the adjusted HRs for endophthalmitis between PLA patients suffering from diabetes and those in whom diabetes was absent. We further analyzed the etiology of cases with endogenous endophthalmitis in this investigation and found Klebsiella pneumonia to be the causative organism among 75.5% of the cases but only 33.4% of the comparison group. CONCLUSIONS: We found that the incidence and risk of developing endophthalmitis was significantly higher among patients with PLA compared with matched controls irrespective of diabetes status.


Assuntos
Endoftalmite/etiologia , Abscesso Hepático Piogênico/complicações , Adolescente , Adulto , Idoso , Bases de Dados Factuais , Endoftalmite/microbiologia , Feminino , Seguimentos , Humanos , Incidência , Infecções por Klebsiella/complicações , Infecções por Klebsiella/microbiologia , Klebsiella pneumoniae/isolamento & purificação , Abscesso Hepático Piogênico/microbiologia , Masculino , Pessoa de Meia-Idade , Programas Nacionais de Saúde/estatística & dados numéricos , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Fatores de Risco , Taiwan , Adulto Jovem
16.
Eur J Gastroenterol Hepatol ; 24(10): 1234-7, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22713510

RESUMO

Multidrug-resistant infections represent an increasing problem in the management of hospitalized patients worldwide. With respect to Gram-negative infections, carbapenems are an important antimicrobial class for the treatment of infections caused by extended-spectrum beta lactamase producers enterobacteriaceae. However, the emergence of novel ß-lactamases with direct carbapenem-hydrolyzing activity has contributed toward an increased prevalence of carbapenem-resistant enterobacteriaceae. Recent reports have described the spread of carbapenemase-producing Klebsiella pneumoniae across the world. There are very few existing agents that can be used against these pathogens and there are limited options on the horizon. In recent years, the epidemiology of bacterial strains involved in the pathogenesis of spontaneous bacterial peritonitis has also been changing rapidly. In this setting, we report the first case of nosocomial spontaneous bacterial peritonitis due to carbapenemase-producing K. pneumoniae.


Assuntos
Carbapenêmicos/uso terapêutico , Fígado Gorduroso/complicações , Infecções por Klebsiella/complicações , Klebsiella pneumoniae/efeitos dos fármacos , Peritonite/microbiologia , Resistência beta-Lactâmica , Carbapenêmicos/farmacologia , Infecção Hospitalar/diagnóstico , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Humanos , Infecções por Klebsiella/diagnóstico , Infecções por Klebsiella/tratamento farmacológico , Klebsiella pneumoniae/isolamento & purificação , Klebsiella pneumoniae/metabolismo , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Peritonite/tratamento farmacológico
17.
Rev Med Chir Soc Med Nat Iasi ; 115(3): 769-75, 2011.
Artigo em Romano | MEDLINE | ID: mdl-22046785

RESUMO

UNLABELLED: Infections in diabetic patient remains an important cause of morbidity and mortality, triggering and maintaining a prolonged metabolic imbalance. Emergence of extented spectrum beta-lactmase (ESBL) in Escherichia coli and Klebsiella pneumoniae is a major concern, because of the atypical manner infection acts in this group of imunodepressed patients and also for the limited therapeutic solutions. For this reason we have evaluated the profile of antimicrobial resistance of these pathogens in both diabetic and non diabetic patients. MATERIAL AND METHOD: The aim of this study was to evaluate, in a retrospective case control study, the antibiotic susceptibility pattern in isolates of E. coli and Klebsiella spp. from different biological products in 49 diabetics and 150 non-diabetics admitted in The Clinical Hospital of Infectious Diseases Iasi over a period of two years. RESULTS: Most of strains of E. coli and Klebsiella spp. ESBL positive were found in uroculture. Significant differences in E. coli resistance rate between diabetics and nondiabetics were noted for amoxicillin-clavulanic acid and ciprofloxacin (31,4% vs.13,98%, p=0,04, respectively 52,9% vs. 24,46%, p=0,004). More isolates of ESBL positive K. pneumoniae were found in diabetic patients (50% vs. 24%). Ciprofloxacin resistance of K. pneumoniae was significantly higher in diabetics (75% vs 39%; p=0,05). There was no resistance in E. coli and K. pneumoniae isolates to imipenem in the diabetic group. CONCLUSIONS: The high resistance rate to quinolones and 3rd generation cefalosporins limits their use for the treatment of Escherichia coli and K. pneumoniae infections. Other alternatives for empiric therapy in community and nosocomial-acquired infections in diabetic patient remains carbapenems, aminoglycosides and colimycin.


Assuntos
Antibacterianos/uso terapêutico , Complicações do Diabetes/tratamento farmacológico , Infecções por Escherichia coli/tratamento farmacológico , Escherichia coli/efeitos dos fármacos , Infecções por Klebsiella/tratamento farmacológico , Klebsiella pneumoniae/efeitos dos fármacos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Aminoglicosídeos/uso terapêutico , Amoxicilina/uso terapêutico , Anti-Infecciosos/uso terapêutico , Carbapenêmicos/uso terapêutico , Estudos de Casos e Controles , Cefalosporinas/uso terapêutico , Criança , Pré-Escolar , Ciprofloxacina/uso terapêutico , Ácido Clavulânico/uso terapêutico , Colistina/uso terapêutico , Farmacorresistência Bacteriana , Escherichia coli/isolamento & purificação , Infecções por Escherichia coli/complicações , Feminino , Humanos , Imipenem/uso terapêutico , Lactente , Infecções por Klebsiella/complicações , Klebsiella pneumoniae/isolamento & purificação , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Quinolonas/uso terapêutico , Resultado do Tratamento
18.
Infez Med ; 19(4): 224-34, 2011 Dec.
Artigo em Italiano | MEDLINE | ID: mdl-22212161

RESUMO

A novel type of carbapenemase, New Delhi metallo beta-lactamase 1 (NDM 1), was first identified in 2008 in two Enterobacteriacea isolates, both recovered from a Swedish patient transferred from India. The emergence of NDM 1 is now reported from all continents, often in patients with a history of travel or hospitalization in the Indian subcontinent. The NDM 1 producing Gram-negative bacteria are mainly Enterobacteriaceae, which can cause colonization or fatal infections, with worrying antimicrobial susceptibility profiles: some isolates have developed resistance to practically all available antibiotics. Is the NDM-1 the super-bug? Are we in the post-antibiotic era? This review is a summary of currently available knowledge of NDM-1 that draws attention to future antimicrobial resistance scenarios.


Assuntos
Abscesso/tratamento farmacológico , Antibacterianos/uso terapêutico , Colistina/uso terapêutico , Complicações do Diabetes , Infecções por Klebsiella/tratamento farmacológico , Klebsiella pneumoniae/efeitos dos fármacos , beta-Lactamases/metabolismo , Abscesso/microbiologia , Antibacterianos/farmacologia , Nádegas , Colistina/farmacologia , Farmacorresistência Bacteriana Múltipla , Humanos , Índia , Infecções por Klebsiella/complicações , Infecções por Klebsiella/microbiologia , Klebsiella pneumoniae/enzimologia , Klebsiella pneumoniae/isolamento & purificação , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Suécia , Viagem , Resultado do Tratamento , beta-Lactamases/efeitos dos fármacos
19.
J Med Microbiol ; 59(Pt 11): 1383-1386, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20688947

RESUMO

The spread of antimicrobial resistance among members of the Enterobacteriaceae is a significant clinical threat. We report the treatment of pan-resistant Klebsiella pneumoniae bacteraemia with combination tigecycline and colistin in a 49-year-old male and review available therapeutic options. Despite a poor prognosis, the patient recovered, but remains colonized with the pan-resistant isolate.


Assuntos
Antibacterianos/administração & dosagem , Bacteriemia/complicações , Colistina/administração & dosagem , Infecções por Klebsiella/complicações , Klebsiella pneumoniae/isolamento & purificação , Minociclina/análogos & derivados , Pneumonia Bacteriana/complicações , Animais , Antibacterianos/farmacologia , Bacteriemia/diagnóstico , Bacteriemia/tratamento farmacológico , Farmacorresistência Bacteriana Múltipla , Quimioterapia Combinada/métodos , Humanos , Infecções por Klebsiella/diagnóstico , Infecções por Klebsiella/tratamento farmacológico , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Minociclina/administração & dosagem , Pneumonia Bacteriana/diagnóstico , Pneumonia Bacteriana/tratamento farmacológico , Tigeciclina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA